Review decision - July 2016

Review of NICE Technology Appraisal Guidance No.288; Dapagliflozin for the treatment of type 2 diabetes (recommendations 1.1 and 1.2)

Decision to defer the review

In August 2015, the decision was made that recommendation 1.3 from TA288 should be updated in a Single Technology Appraisal. An appraisal for this indication is now in development and has an anticipated publication date of January 2017.

At this time it was agreed that the consideration of a review of recommendations 1.1 and 1.2 should be deferred until the publication of the forthcoming clinical guideline for the management of type 2 diabetes. This clinical guideline (NG28) was published in December 2015 and the wording of recommendation 1.1 from TA288 was subsequently re-worded to reflect changes made in the new clinical guideline.

Recommendations 1.1 and 1.2 consider the use of dapagliflozin as dual therapy and a combination therapy options. There are two other published appraisals for type 2 diabetes that look at dual therapy and combination therapy and it would be more efficient to consider these topics in a single review proposal.

Consequently we have decided to defer the consideration of the review until May 2017, when recommendations 1.1 and 1.2 of TA288 will be considered for review alongside TA315; Canagliflozin in combination therapy for treating type 2 diabetes and TA336; Empagliflozin for treating type 2 diabetes.

This page was last updated: